umbralisib (Ukoniq) Report issue

Small molecule Orphan Drug FDA Approved FDA Breakthrough Therapy FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

  • Now
Umbralisib, sold under the brand name Ukoniq, is an anti-cancer medication for the treatment of marginal zone lymphoma (MZL) and follicular lymphoma (FL). It is taken by mouth.   Wikipedia

  • SMILES: CC(C)Oc1ccc(cc1F)c2nn([C@@H](C)C3=C(C(=O)c4cc(F)ccc4O3)c5cccc(F)c5)c6ncnc(N)c26
  • Mol. Mass: 571.56
  • ALogP: 6.66
  • ChEMBL Molecules:
More Chemistry
tgr-1202 | umbralisib


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue